COVID VACCINE TRIAL
VB10.COV2 VB-D-01
For information about the trial – Information in Norwegian:
An open label, Phase 1/2, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2). Three dose levels will be tested. IM administrations 21 days apart.
ClinicalTrials.gov Identifier: NCT05069623